第2屆NBRP Pitch Day潛力團隊獎-「以非編碼核酸發展DDB2抑制劑作為乳癌化療增敏劑」

化療是所有乳癌亞型的標準治療，但整體反應率僅為50%。NuPlus為解決臨床需求，旨在成為第一個以DDB2為靶點的核酸藥物，透過增加化療敏感性、減少藥物劑量及副作用、有效抑制腫瘤，提供患者更好的治療選擇。NuPlus以脂質奈米顆粒（LNP）作為藥物遞送的策略。在完成PoC階段後，NuPlus即將進入關鍵的藥物開發階段，我們在台灣萌芽計劃經費補助下，將進行藥理效力驗證、初步安全性評估和基本藥代動力學測試，為進入臨床前試驗階段做準備。

Chemotherapy is the standard treatment for all breast cancer subtypes, but the overall response rate is only 50%. NuPlus aims to address this clinical need by becoming the first nucleic acid drug targeting DDB2. It enhances chemotherapy sensitivity, reduces drug dosage and side effects, and effectively inhibits tumor growth, providing patients with better treatment options. NuPlus utilizes lipid nanoparticles (LNP) as its drug delivery strategy. After completing the PoC phase, NuPlus is now entering the critical drug development stage. With funding from Taiwan's Sprout Project, we will conduct pharmacological efficacy studies, preliminary safety assessments, and basic pharmacokinetic tests in preparation for the preclinical trial phase.

團隊成員包含黃偉謙 教授、劉良智 教授、周心喬 博士、何宥豪 博士、魏雅鈴、黃至豪 醫師